Emily K Bergsland
Alliance for Clinical Trials in Oncology · University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emily K Bergsland as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:27 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01841736 · Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsNational Cancer Institute (NCI) · active not recruiting · Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1 · principal investigator
- Ph2NCT00843531 · RAD001 and Erlotinib in Patients With Neuroendocrine TumorsUniversity of California, San Francisco · terminated · Neuroendocrine Tumors · principal investigator
- Ph1NCT00390156 · Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid TumorsUniversity of California, San Francisco · completed · Unspecified Adult Solid Tumor · study chair
- Ph2/Ph3NCT00227617 · Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUniversity of California, San Francisco · terminated · Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Research Training and Education CoordinationP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2018 to 2026 · $361,621 awarded in 2026Same name and institution; not confirmed by an ID
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2021 to 2025 · $643,767 awarded in 2025Same name and institution; not confirmed by an ID
- SU11248 IN PATIENTS WITH ADVANCED UNRESECTABLE NEUROENDOCRINE TUMORM01RR000079 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2004 to 2005 · $467 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT01841736
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT01841736
- NCI NCTN- Network Lead Academic Participating Site: USCU10CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Anthony Boutros El-Khoueiry, HEINZ JOSEF LENZ, DAVID IAN QUINN · fiscal years 2014 to 2018Named on NCT01841736
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:27 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.J Immunother Cancer · 2017283 citationsRCR 8.5
- 266 citationsRCR 8.0
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Clin Oncol · 2006151 citationsRCR 3.4
- Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.J Clin Oncol · 2007135 citationsRCR 2.8
- Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.Br J Cancer · 2005133 citationsRCR 2.8
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 200786 citationsRCR 2.2
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.Cancer Chemother Pharmacol · 201064 citationsRCR 1.4
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Invest New Drugs · 200859 citationsRCR 1.3
- Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.Pancreas · 201652 citationsRCR 2.0
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.Ann Oncol · 201351 citationsRCR 1.4